A COMPREHENSIVE REVIEW ON APPLICATION OF HYALURONIC ACID IN DEVELOPMENT OF NOVEL DRUG DELIVERY SYSTEMS

VAISHNAVI DESHMUKH; NILESH KULKARNI; MAHESHWARI NAVGHARE

doi:10.22159/ijcpr.2025v17i5.7021

Authors

VAISHNAVI DESHMUKH Department of Pharmaceutics, PES Modern College of Pharmacy (for ladies), Moshi, Pune-412105, Maharashtra, India https://orcid.org/0009-0008-0273-4055
NILESH KULKARNI Department of Pharmaceutics, PES Modern College of Pharmacy (for ladies), Moshi, Pune-412105, Maharashtra, India
MAHESHWARI NAVGHARE Department of Pharmaceutics, PES Modern College of Pharmacy (for ladies), Moshi, Pune-412105, Maharashtra, India https://orcid.org/0009-0009-8907-0905

DOI:

https://doi.org/10.22159/ijcpr.2025v17i5.7021

Keywords:

Hyaluronic acid, Novel drug delivery system, , Derivative of hyaluronic acid, micelle, , niosomes, liposomes

Abstract

Hyaluronic acid is a naturally present linear polysaccharide that contributes to various structural and physiological function in the human body. Its unique properties have led to its extensive exploration in various drug delivery system, including nasal, transdermal, parenteral, pulmonary, implantable, ocular, and gene delivery. HA chemical structural modification have enabled the development of diverse formulation, such as micelles, niosomes, liposomes, solid lipid nanoparticle, microsphere, and cyclodextrin which have shown promising results in enhancing drug bioavailability, targeting specific cells, and providing sustained release. HA mucoadhesive properties, ability to interact with specific receptor, and biocompatibility have made it an attractive biomolecule for pharmaceutical and medical advancements. This abstract highlighting the versatility and potential of HA in improving therapeutic efficacy and reducing side effect in various diseases condition.

Downloads

Download data is not yet available.

References

1. Lambe S, Ghogare P, Sonawane S, Shinde L, Prashant D. Isolation purification and characterization of hyaluronic acid: a concise review. J Pharmacogn Phytochem. 2021;10(3):500-6.

2. Liao YH, Jones SA, Forbes B, Martin GP, Brown MB. Hyaluronan: pharmaceutical characterization and drug delivery. Drug Deliv. 2005;12(6):327-42. doi: 10.1080/10717540590952555, PMID 16253949.

3. Woo JS, Piao MG, Li DX, Ryu DS, Choi JY, Kim JA. Development of cyclosporin a loaded hyaluronic microsphere with enhanced oral bioavailability. Int J Pharm. 2007;345(1-2):134-41. doi: 10.1016/j.ijpharm.2007.08.050, PMID 17950545.

4. Saturnino C, Sinicropi MS, Parisi OI, Iacopetta D, Popolo A, Marzocco S. Acetylated hyaluronic acid: enhanced bioavailability and biological studies. BioMed Res Int. 2014;2014:921549. doi: 10.1155/2014/921549, PMID 25114930, PMCID PMC3974741.

5. Kafedjiiski K, Jetti RK, Foger F, Hoyer H, Werle M, Hoffer M. Synthesis and in vitro evaluation of thiolated hyaluronic acid for mucoadhesive drug delivery. Int J Pharm. 2007;343(1-2):48-58. doi: 10.1016/j.ijpharm.2007.04.019, PMID 17544606.

6. Fernandez Marino I, Anfray C, Crecente Campo J, Maeda A, Ummarino A, Teijeiro-Valino C. Mannose modified hyaluronic acid nanocapsules for the targeting of tumor associated macrophages. Drug Deliv Transl Res. 2023;13(7):1896-911. doi: 10.1007/s13346-022-01265-9, PMID 36472784.

7. Zhu J, Tang X, Jia Y, Ho CT, Huang Q. Applications and delivery mechanisms of hyaluronic acid used for topical/transdermal delivery a review. Int J Pharm. 2020;578:119127. doi: 10.1016/j.ijpharm.2020.119127, PMID 32036009.

8. Charan TR, Bhutto MA, Bhutto MA, Tunio AA, Khuhro GM, Khaskheli SA. Nanomaterials of curcumin hyaluronic acid: their various methods of formulations clinical and therapeutic applications present gap and future directions. Futur J Pharm Sci. 2021;7(1):126. doi: 10.1186/s43094-021-00281-9, PMID 34956958.

9. Yan K, Feng Y, Gao K, Shi X, Zhao X. Fabrication of hyaluronic acid based micelles with glutathione responsiveness for targeted anticancer drug delivery. J Colloid Interface Sci. 2022;606(2):1586-96. doi: 10.1016/j.jcis.2021.08.129, PMID 34500160.

10. Kim K, Choi H, Choi ES, Park MH, Ryu JH. Hyaluronic acid coated nanomedicine for targeted cancer therapy. Pharmaceutics. 2019;11(7):301. doi: 10.3390/pharmaceutics11070301, PMID 31262049, PMCID PMC6678697.

11. Cheng Z, Lin H, Wang Z, Yang X, Zhang M, Liu X. Preparation and characterization of dissolving hyaluronic acid composite microneedles loaded micelles for delivery of curcumin. Drug Deliv Transl Res. 2020;10(5):1520-30. doi: 10.1007/s13346-020-00735-2, PMID 32100266.

12. Zhang Z, Chen M, Wang J, Liu M, Guo R, Zhang L. Hyaluronic acid modified micelles of azithromycin and quercetin against infections caused by methicillin resistant Staphylococcus aureus. Int J Nanomedicine. 2024;19:9637-58. doi: 10.2147/IJN.S476471, PMID 39309186.

13. Tang X, Kurban M, Hafiz I, Shen Q, Wang M. Preparation of hyaluronic acid-loaded harmine polymeric micelles and in vitro effect anti-breast cancer. Eur J Pharm Sci. 2023 Apr 1;183:106388. doi: 10.1016/j.ejps.2023.106388, PMID 36758771.

14. Chen SC, Yang MH, Chung TW, Jhuang TS, Yang JD, Chen KC. Preparation and characterization of hyaluronic acid polycaprolactone copolymer micelles for the drug delivery of radioactive iodine-131 labeled lipiodol. BioMed Res Int. 2017;2017:4051763. doi: 10.1155/2017/4051763, PMID 28127555, PMCID PMC5621360.

15. Wang J, Li Y, Wang L, Wang X, Tu P. Comparison of hyaluronic acid based micelles and polyethylene glycol based micelles on reversal of multidrug resistance and enhanced anticancer efficacy in vitro and in vivo. Drug Deliv. 2018;25(1):330-40. doi: 10.1080/10717544.2018.1428385, PMID 29350064.

16. Zhang X, Ren X, Tang J, Wang J, Zhang X, He P. Hyaluronic acid reduction sensitive polymeric micelles achieving co-delivery of tumor targeting paclitaxel/apatinib effectively reverse cancer multidrug resistance. Drug Deliv. 2020;27(1):825-35. doi: 10.1080/10717544.2020.1770373, PMID 32489129.

17. Hanieh PN, Forte J, Di Meo C, Ammendolia MG, Del Favero E, Cantu L. Hyaluronic acid derivative effect on niosomal coating and interaction with cellular mimetic membranes. Molecules. 2021 Jun 5;26(11):3434. doi: 10.3390/molecules26113434, PMID 34198955, PMCID PMC8235224.

18. Abdelkader H, Alani AW, Alany RG. Recent advances in non-ionic surfactant vesicles (niosomes): self-assembly fabrication characterization drug delivery applications and limitations. Drug Deliv. 2014 Mar 1;21(2):87-100. doi: 10.3109/10717544.2013.838077, PMID 24156390.

19. Bagheri A, Chu BS, Yaakob H. Niosomal drug delivery systems: formulation preparation and applications. World Appl Sci J. 2014;32(8):1671-85. doi: 10.5829/idosi.wasj.2014.32.08.848.

20. Mansoori Kermani A, Khalighi S, Akbarzadeh I, Niavol FR, Motasadizadeh H, Mahdieh A. Engineered hyaluronic acid decorated niosomal nanoparticles for controlled and targeted delivery of epirubicin to treat breast cancer. Mater Today Bio. 2022;16:100349. doi: 10.1016/j.mtbio.2022.100349, PMID 35875198.

21. Zeng W, Li Q, Wan T, Liu C, Pan W, Wu Z. Hyaluronic acid coated niosomes facilitate tacrolimus ocular delivery: mucoadhesion precorneal retention aqueous humor pharmacokinetics and transcorneal permeability. Colloids Surf B Biointerfaces. 2016 May 1;141:28-35. doi: 10.1016/j.colsurfb.2016.01.014, PMID 26820107.

22. Wichayapreechar P, Anuchapreeda S, Phongpradist R, Rungseevijitprapa W, Ampasavate C. Dermal targeting of Centella asiatica extract using hyaluronic acid surface modified niosomes. J Liposome Res. 2020 Apr 2;30(2):197-207. doi: 10.1080/08982104.2019.1614952, PMID 31060402.

23. Hanieh PN, Forte J, Di Meo C, Ammendolia MG, Del Favero E, Cantu L. Hyaluronic acid derivative effect on niosomal coating and interaction with cellular mimetic membranes. Molecules. 2021 Jun 5;26(11):3434. doi: 10.3390/molecules26113434, PMID 34198955.

24. Anirudhan TS, Vasantha CS, Sasidharan AV. Layer-by-layer assembly of hyaluronic acid/carboxymethylchitosan polyelectrolytes on the surface of aminated mesoporous silica for the oral delivery of 5-fluorouracil. Eur Polym J. 2017 Aug 1;93:572-89. doi: 10.1016/j.eurpolymj.2017.06.033.

25. Wichayapreechar P, Anuchapreeda S, Phongpradist R, Rungseevijitprapa W, Ampasavate C. Dermal targeting of Centella asiatica extract using hyaluronic acid surface modified niosomes. J Liposome Res. 2020 Apr 2;30(2):197-207. doi: 10.1080/08982104.2019.1614952, PMID 31060402.

26. Kong M, Park H, Feng C, Hou L, Cheng X, Chen X. Construction of hyaluronic acid noisome as functional transdermal nanocarrier for tumor therapy. Carbohydr Polym. 2013 Apr 15;94(1):634-41. doi: 10.1016/j.carbpol.2013.01.091, PMID 23544584.

27. Sadeghi Ghadi Z, Ebrahimnejad P, Talebpour Amiri F, Nokhodchi A. Improved oral delivery of quercetin with hyaluronic acid containing niosomes as a promising formulation. J Drug Target. 2021 Feb 7;29(2):225-34. doi: 10.1080/1061186X.2020.1830408, PMID 32997536.

28. Mansoori Kermani A, Khalighi S, Akbarzadeh I, Niavol FR, Motasadizadeh H, Mahdieh A. Engineered hyaluronic acid decorated niosomal nanoparticles for controlled and targeted delivery of epirubicin to treat breast cancer. Mater Today Bio. 2022;16:100349. doi: 10.1016/j.mtbio.2022.100349, PMID 35875198.

29. Kaveh Zenjanab M, Abdolahinia ED, Alizadeh E, Hamishehkar H, Shahbazi R, Ranjbar Navazi Z. Hyaluronic acid targeted niosomes for effective breast cancer chemostarvation therapy. ACS Omega. 2024 Feb 22;9(9):10875-85. doi: 10.1021/acsomega.3c09782, PMID 38463340.

30. Khalid W, Shah KU, Saeed MD, Nawaz A, Rehman FU, Shoaib M. 5-fluorouracil loaded hyaluronic acid coated niosomal vesicles: fabrication and ex vivo evaluation for skin drug delivery. ACS Omega. 2023 Nov 27;8(48):45405-13. doi: 10.1021/acsomega.3c04457, PMID 38075815.

31. Matalqah S, Lafi Z, Asha SY. Hyaluronic acid in nanopharmaceuticals: an overview. Curr Issues Mol Biol. 2024 Sep 20;46(9):10444-61. doi: 10.3390/cimb46090621, PMID 39329973.

32. Kutbi HI, Asfour HZ, Kammoun AK, Sirwi A, Cavalu S, Gad HA. Optimization of hyaluronate based liposomes to augment the oral delivery and the bioavailability of berberine. Materials (Basel). 2021 Oct 2;14(19):5759. doi: 10.3390/ma14195759, PMID 34640154.

33. Mansoori B, Mohammadi A, Abedi Gaballu F, Abbaspour S, Ghasabi M, Yekta R. Hyaluronic acid decorated liposomal nanoparticles for targeted delivery of 5-fluorouracil into HT-29 colorectal cancer cells. J Cell Physiol. 2020 Oct;235(10):6817-30. doi: 10.1002/jcp.29576, PMID 31989649.

34. Song M, Liang Y, Li K, Zhang J, Zhang N, Tian B. Hyaluronic acid modified liposomes for targeted delivery of doxorubicin and paclitaxel to CD44 overexpressing tumor cells with improved dual drugs synergistic effect. J Drug Deliv Sci Technol. 2019 Oct 1;53:101179. doi: 10.1016/j.jddst.2019.101179.

35. Garg G, Garg S, Patel P, Gupta GD, Kurmi BD. Advances in solid lipid nanoparticle chemistry as drug delivery vehicles. Int J Polym Mater Polym Biomater. 2025 Apr 13;74(6):523-37. doi: 10.1080/00914037.2024.2344603.

36. Campos J, Varas Godoy M, Haidar ZS. Physicochemical characterization of chitosan hyaluronan coated solid lipid nanoparticles for the targeted delivery of paclitaxel: a proof-of-concept study in breast cancer cells. Nanomedicine (Lond). 2017 Mar;12(5):473-90. doi: 10.2217/nnm-2016-0371, PMID 28181464.

37. Shen H, Shi S, Zhang Z, Gong T, Sun X. Coating solid lipid nanoparticles with hyaluronic acid enhances antitumor activity against melanoma stemlike cells. Theranostics. 2015 Apr 5;5(7):755-71. doi: 10.7150/thno.10804, PMID 25897340, PMCID PMC4414389.

38. Tran TH, Choi JY, Ramasamy T, Truong DH, Nguyen CN, Choi HG. Hyaluronic acid coated solid lipid nanoparticles for targeted delivery of vorinostat to CD44 overexpressing cancer cells. Carbohydr Polym. 2014 Dec 19;114:407-15. doi: 10.1016/j.carbpol.2014.08.026, PMID 25263908, PMCID PMC4277021.

39. Lee SE, Lee CD, Ahn JB, Kim DH, Lee JK, Lee JY. Hyaluronic acid coated solid lipid nanoparticles to overcome drug resistance in tumor cells. J Drug Deliv Sci Technol. 2019 Apr;50:365-71. doi: 10.1016/j.jddst.2019.01.042.

40. Huang G, Chen J. Preparation and applications of hyaluronic acid and its derivatives. Int J Biol Macromol. 2019;125:478-84. doi: 10.1016/j.ijbiomac.2018.12.074, PMID 30529556.

41. Woo JS, Piao MG, Li DX, Ryu DS, Choi JY, Kim JA. Development of cyclosporin a loaded hyaluronic microsphere with enhanced oral bioavailability. Int J Pharm. 2007;345(1-2):134-41. doi: 10.1016/j.ijpharm.2007.08.050, PMID 17950545.

42. Huh Y, Cho HJ, Yoon IS, Choi MK, Kim JS, Oh E. Preparation and evaluation of spray dried hyaluronic acid microspheres for intranasal delivery of fexofenadine hydrochloride. Eur J Pharm Sci. 2010;40(1):9-15. doi: 10.1016/j.ejps.2010.02.002, PMID 20149868.

43. Hesler M, Schwarz DH, Dahnhardt Pfeiffer S, Wagner S, Von Briesen H, Wenz G. Synthesis and in vitro evaluation of cyclodextrin hyaluronic acid conjugates as a new candidate for intestinal drug carrier for steroid hormones. Eur J Pharm Sci. 2020 Feb 15;143:105181. doi: 10.1016/j.ejps.2019.105181, PMID 31852628, PMCID PMC6905483.

44. Bognanni N, Viale M, Sabatino G, Pappalardo G, Vecchio G. New conjugates of hyaluronic acid with γ‐cyclodextrin as sorafenib carrier in cancer cells. Chem Med Chem. 2024 Sep 16;19(18):e202400219. doi: 10.1002/cmdc.202400219, PMID 38856008.

45. Singh P, Wu L, Ren X, Zhang W, Tang Y, Chen Y. Hyaluronic acid based β-cyclodextrin grafted copolymers as biocompatible supramolecular hosts to enhance the water solubility of tocopherol. Int J Pharm. 2020;586:119542. doi: 10.1016/j.ijpharm.2020.119542, PMID 32553494.

46. Wang J, Muhammad N, Li T, Wang H, Liu Y, Liu B. Hyaluronic acid coated camptothecin nanocrystals for targeted drug delivery to enhance anticancer efficacy. Mol Pharm. 2020;17(7):2411-25. doi: 10.1021/acs.molpharmaceut.0c00161, PMID 32437163.

47. Piperno A, Zagami R, Cordaro A, Pennisi R, Musarra Pizzo M, Scala A. Exploring the entrapment of antiviral agents in hyaluronic acid cyclodextrin conjugates. J Incl Phenom Macrocycl Chem. 2019 Feb;93(1-2):33-40. doi: 10.1007/s10847-018-0829-6.

48. Horvat S, Feher A, Wolburg H, Sipos P, Veszelka S, Toth A. Sodium hyaluronate as a mucoadhesive component in nasal formulation enhances delivery of molecules to brain tissue. Eur J Pharm Biopharm. 2009;72(1):252-9. doi: 10.1016/j.ejpb.2008.10.009, PMID 19007885.

49. Garcia Garcia E, Andrieux K, Gil S, Couvreur P. Colloidal carriers and blood brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int J Pharm. 2005;298(2):274-92. doi: 10.1016/j.ijpharm.2005.03.031, PMID 15896933.

50. Wolburg H, Wolburg Buchholz K, Sam H, Horvat S, Deli MA, Mack AF. Epithelial and endothelial barriers in the olfactory region of the nasal cavity of the rat. Histochem Cell Biol. 2008 Jul;130(1):127-40. doi: 10.1007/s00418-008-0410-2, PMID 18340454.

51. Lim ST, Forbes B, Berry DJ, Martin GP, Brown MB. In vivo evaluation of novel hyaluronan/chitosan microparticulate delivery systems for the nasal delivery of gentamicin in rabbits. Int J Pharm. 2002;231(1):73-82. doi: 10.1016/s0378-5173(01)00873-0, PMID 11719016.

52. Casula E, Manca ML, Perra M, Pedraz JL, Lopez Mendez TB, Lozano A. Nasal spray formulations based on combined hyalurosomes and glycerosomes loading Zingiber officinalis extract as green and natural strategy for the treatment of rhinitis and rhinosinusitis. Antioxidants (Basel). 2021 Jul 11;10(7):1109. doi: 10.3390/antiox10071109, PMID 34356342, PMCID PMC8307322.

53. Morimoto K, Yamaguchi H, Iwakura Y, Morisaka K, Ohashi Y, Nakai Y. Effects of viscous hyaluronate sodium solutions on the nasal absorption of vasopressin and an analogue. Pharm Res. 1991;8(4):471-4. doi: 10.1023/a:1015894910416, PMID 1871041.

54. Liu S, Jin MN, Quan YS, Kamiyama F, Katsumi H, Sakane T. The development and characteristics of novel microneedle arrays fabricated from hyaluronic acid and their application in the transdermal delivery of insulin. J Control Release. 2012;161(3):933-41. doi: 10.1016/j.jconrel.2012.05.030, PMID 22634072.

55. Fakhraei Lahiji S, Kim Y, Kang G, Kim S, Lee S, Jung H. Tissue interlocking dissolving microneedles for accurate and efficient transdermal delivery of biomolecules. Sci Rep. 2019 May 27;9(1):7886. doi: 10.1038/s41598-019-44418-6, PMID 31133711, PMCID PMC6548007.

56. Ahmad NN, Ghazali NN, Wong YH. Concept design of transdermal microneedles for diagnosis and drug delivery: a review. Adv Eng Mater. 2021 Dec;23(12):2100503. doi: 10.1002/adem.202100503.

57. Bonet IJ, Araldi D, Green PG, Levine JD. Topical co-application of hyaluronan with transdermal drug delivery enhancers attenuates inflammatory and neuropathic pain. Pain. 2023;164(11):2653-64. doi: 10.1097/j.pain.0000000000002884, PMID 37465123, PMCID PMC10035890.

58. Araldi D, Ferrari LF, Levine JD. Hyperalgesic priming (type II) induced by repeated opioid exposure: maintenance mechanisms. Pain. 2017 Jul;158(7):1204-16. doi: 10.1097/j.pain.0000000000000898, PMID 28306605, PMCID PMC5547424.

59. Junqueira LA, Polonini H, Loures S, Raposo NR, Ferreira AO, Brandao MA. Permeation efficacy of a transdermal vehicle with steroidal hormones and nonsteroidal anti-inflammatory agents as model drugs. Curr Drug Deliv. 2019 Feb 1;16(2):136-41. doi: 10.2174/1567201815666181024141849, PMID 30360741, PMCID PMC6718335.

60. Son SU, Lim JW, Kang T, Jung J, Lim EK. Hyaluronan based nanohydrogels as effective carriers for transdermal delivery of lipophilic agents: towards transdermal drug administration in neurological disorders. Nanomaterials (Basel). 2017 Dec 4;7(12):427. doi: 10.3390/nano7120427, PMID 29207551, PMCID PMC5743394.

61. Luo Y, Prestwich GD. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug Chem. 1999 Sep 20;10(5):755-63. doi: 10.1021/bc9900338, PMID 10502340, PMCID PMC3552684.

62. Luo Y, Ziebell MR, Prestwich GD. A hyaluronic acid taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules. 2000 Jun 13;1(2):208-18. doi: 10.1021/bm000283n, PMID 11710102, PMCID PMC3564927.

63. Sakurai K, Andoh M, Yamada M, Kodera Y, Nishimura H, Hiroto M. Suppression of ischemic edema in mice by manganese hyaluronate conjugate. Japan J Pharmacol. 1997;74(1):117-20. doi: 10.1254/jjp.74.117, PMID 9195308.

64. Sakurai K, Miyazaki K, Kodera Y, Nishimura H, Shingu M, Inada Y. Anti-inflammatory activity of superoxide dismutase conjugated with sodium hyaluronate. Glycoconj J. 1997;14(6):723-8. doi: 10.1023/a:1018521501289, PMID 9337085.

65. Morimoto K, Metsugi K, Katsumata H, Iwanaga K, Kakemi M. Effects of low-viscosity sodium hyaluronate preparation on the pulmonary absorption of rh-insulin in rats. Drug Dev Ind Pharm. 2001;27(4):365-71. doi: 10.1081/ddc-100103737, PMID 11411905.

66. Surendrakumar K, Martyn GP, Hodgers EC, Jansen M, Blair JA. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J Control Release. 2003 Sep 4;91(3):385-94. doi: 10.1016/s0168-3659(03)00263-3, PMID 12932716.

67. Takayama K, Hirata M, Machida Y, Masada T, Sannan T, Nagai T. Effect of interpolymer complex formation on bioadhesive property and drug release phenomenon of compressed tablet consisting of chitosan and sodium hyaluronate. Chem Pharm Bull (Tokyo). 1990 Jul;38(7):1993-7. doi: 10.1248/cpb.38.1993, PMID 2268902.

68. Sasaki H, Yamamura K, Nishida K, Nakamura J, Ichikawa M. Delivery of drugs to the eye by topical application. Prog Retin Eye Res. 1996;15(2):583-620. doi: 10.1016/1350-9462(96)00014-6, PMID 8793623.

69. Lapcik L JR and L, Lapcik L, De Smedt S, Demeester J, Chabrecek P. Hyaluronan: preparation structure properties and applications. Chem Rev. 1998;98(8):2663-84. doi: 10.1021/cr941199z, PMID 11848975.

70. Langer K, Mutschler E, Lambrecht G, Mayer D, Troschau G, Stieneker F. Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery. International Journal of Pharmaceutics. 1997;158(2):219-31. doi: 10.1016/S0378-5173(97)00255-X.

71. Saettone MF, Chetoni P, Tilde Torracca M, Burgalassi S, Giannaccini B. Evaluation of muco-adhesive properties and in vivo activity of ophthalmic vehicles based on hyaluronic acid. International Journal of Pharmaceutics. 1989;51(3):203-12. doi: 10.1016/0378-5173(89)90193-2.

72. Kim A, Checkla DM, Dehazya P, Chen W. Characterization of DNA-hyaluronan matrix for sustained gene transfer. J Control Release. 2003;90(1):81-95. doi: 10.1016/s0168-3659(03)00175-5, PMID 12767709.

73. Yun YH, Goetz DJ, Yellen P, Chen W. Hyaluronan microspheres for sustained gene delivery and site specific targeting. Biomaterials. 2004;25(1):147-57. doi: 10.1016/s0142-9612(03)00467-8, PMID 14580918.

74. Hua S, Marks E, Schneider JJ, Keely S. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomedicine. 2015 Jul;11(5):1117-32. doi: 10.1016/j.nano.2015.02.018, PMID 25784453, PMCID PMC4388435.

75. Kotla NG, Burke O, Pandit A, Rochev Y. An orally administrated hyaluronan functionalized polymeric hybrid nanoparticle system for colon specific drug delivery. Nanomaterials (Basel). 2019 Sep 2;9(9):1246. doi: 10.3390/nano9091246, PMID 31480704, PMCID PMC6769880.

76. Batist G, Gelmon KA, Chi KN, Miller WH JR, Chia SK, Mayer LD. Safety pharmacokinetics and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res. 2009 Jan 15;15(2):692-700. doi: 10.1158/1078-0432.CCR-08-0515, PMID 19147776, PMCID PMC2680456.

77. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013 Jan;65(1):36-48. doi: 10.1016/j.addr.2012.09.037, PMID 23036225, PMCID PMC4506350.